Explore therapeutic choices for patients with treatment-resistant depression, including ketamine, psilocybin, and various ...

Adults with congenital heart disease benefit from routine care at ACHD centers and collaboration with ACHD cardiologists ...

When the flu strikes, it can feel relentless: rising fever, hacking cough, stuffy nose and sore throat. For many people, relief can come in the form of Tamiflu, a prescription antiviral medication ...

Among pediatric and adult patients with cystic fibrosis, the average number of chronic respiratory therapies used fell after ...

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, ...

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), ...

H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Milestone Pharmaceuticals (MIST) to $8 from $5 and keeps a Buy rating on the shares following the approval of Cardamyst for the ...

Milestone Pharmaceuticals (NASDAQ:MIST) shares jumped roughly 35% after the U.S. Food and Drug Administration approved ...

Summary • Milestone Pharmaceuticals Inc. (MIST) shares surged 39% to $3.35 in pre-market trading following FDA approval of CARDAMYST™.• CARDAMYST™ is the first self-administered nasal spray for ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given ...

Investing.com -- Milestone Pharmaceuticals (NASDAQ:MIST) stock surged 35% after the company received FDA approval for CARDAMYST, the first self-administered nasal spray for adults with paroxysmal ...

The US FDA has approved etripamil (Cardamyst) nasal spray for the self-administered treatment of acute symptomatic paroxysmal supraventricular tachycardia (PSVT) in adults. This approval, ...